真实世界研究:RA患者启动JAK或TNF抑制剂后临床、可穿戴生物传感器与患者报告结局的变化
该研究纳入299例中高疾病活动度RA患者,在社区风湿科诊所启动upadacitinib或adalimumab治疗并观察≥12周,收集临床、PROMIS患者报告结局(PRO)及Fitbit生物传感器数据。结果显示CDAI平均改善13个单位,疼痛干扰、疲劳和睡眠障碍评分改善4-5单位,PRO变化可解释CDAI变化52%的变异。
要点
- RA患者启动upadacitinib或adalimumab后CDAI平均改善13个单位,PRO评分改善4-5单位。
- CDAI与PROs呈中度相关(r=0.38-0.56),PRO变化解释52%的CDAI变化变异。
- 基线久坐患者的活动量也有改善,可穿戴设备可用于院外追踪疾病状态。
核心结论
- RA患者启动upadacitinib或adalimumab治疗后,临床、PRO和生物传感器多种数据类型均观察到治疗反应。
- 院外追踪RA疾病活动可能有助于评估疾病状态和优化治疗调整,即使没有医生 derived 的测量指标。
研究设计与样本
- 前瞻性真实世界观察研究,纳入美国28家社区风湿科诊所的中高疾病活动度(CDAI>10)RA患者,2021年3月至2022年10月入组,观察≥12周。
- 患者被处方upadacitinib或adalimumab,通过PatientSpot应用收集PROMIS疾病活动和症状指标,使用腕戴Fitbit设备收集生物传感器活动数据。
- 299例患者被招募,204例(68%)在30天内开始upadacitinib或adalimumab;150例(50%)提供临床和PRO数据,主研究人群中95例(63%)提供生物传感器数据。
- 使用Pearson R相关和线性回归模型分析随时间的变化及数据类型间的关联。
主要发现
- 从基线到随访,平均CDAI改善13个单位,PROMIS疼痛干扰、疲劳和睡眠障碍评分改善4至5个单位。
- 基线时被认为久坐的患者活动量也有改善。
- CDAI与PROs之间的中度相关性范围为0.38至0.56。
- 线性回归模型显示,PROs的变化解释了CDAI变化变异的52%。
临床怎么用
- 对于启动upadacitinib或adalimumab的RA患者,可考虑使用PROMIS等PRO工具和可穿戴设备进行院外疾病活动追踪。
- PROs的变化与CDAI变化中度相关,可作为评估治疗反应和调整治疗的参考,尤其在缺乏医生测量指标时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate rheumatoid arthritis (RA) symptoms and disease activity among patients initiating new treatment, we examined clinical, patient-reported outcome (PRO), and wearable biosensor data, and we explored longitudinal associations among these three data types. METHODS: Patients with RA with moderate-to-high disease activity (Clinical Disease Activity Index (CDAI) >10) and prescribed upadacitinib or adalimumab were enrolled (March 2021-October 2022) during in-office visits at 28 community rheumatology clinics in the United States and were observed for ≥12 weeks. At-home data collection included disease activity and symptom measures from the Patient-Reported Outcomes Measurement Information System (PROMIS) using the PatientSpot app. Biosensor activity data were collected with a wrist-worn Fitbit device. Changes over time and associations among data types were analyzed with Pearson R correlations and linear regression models. RESULTS: Of 299 patients recruited, 204 (68%) started upadacitinib or adalimumab within 30 days; 150 (50%) provided clinical and PRO data, and of the main study population, 95 patients (63%) provided biosensor data. Mean CDAI improved 13 units and PROMIS Pain Interference, Fatigue, and Sleep Disturbance scores improved by 4 to 5 units from baseline to follow-up. Activity improved for patients considered sedentary at baseline. Moderate correlations between CDAI and PROs ranged from 0.38 to 0.56. Linear regression model showed that changes in PROs explained 52% of the variability in change in CDAI. CONCLUSION: Treatment response is observed across diverse data types and tracking RA disease activity outside of the clinic for patients initiating new treatments may be useful in evaluating disease status and optimal changes in therapy, even in the absence of physician-derived measures.
引用
- Nowell WB, Stradford L, Su Y, et al. Real-World Study to Evaluate Change in Clinical, Wearable Biosensor and Patient-Reported Outcomes Among Patients With Rheumatoid Arthritis Initiating Treatment With a JAK or Tumor Necrosis Factor Inhibitor. Arthritis Care Res (Hoboken). 2026. PMID: 42527849. doi:10.1002/acr.80124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。